Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Csl Ltd ADR (CSLLY)

Csl Ltd ADR (CSLLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

/PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL) (USOTC: CSLLY) announced today that Jeffrey Ball, an established global leader across multiple...

CSL : 409.36 (+0.21%)
CSLLY : 93.2353 (+1.54%)
5 Diverse Medical Stocks to Buy for 2023 and Beyond

The top and bottom-line growth make these Zacks Medical stocks very attractive.

NVO : 127.60 (+0.72%)
HUM : 328.90 (+1.47%)
CHGCY : 15.7800 (-0.44%)
HZNP : 116.30 (+0.04%)
CSLLY : 93.2353 (+1.54%)
What Makes CSL Limited Sponsored ADR (CSLLY) a Good Fit for 'Trend Investing'

CSL Limited Sponsored ADR (CSLLY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made...

CSLLY : 93.2353 (+1.54%)
Why CSL Ltd Stock Could Be Worth a Look

FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment.

CSL : 409.36 (+0.21%)
CSLLY : 93.2353 (+1.54%)
NVS : 99.79 (+0.19%)
BLUE : 1.0800 (+10.81%)
ARCT : 28.06 (+3.12%)
Why Arcturus Therapeutics Stock Is Skyrocketing Today

Investors are applauding Arcturus' collaboration with CSL.

CSL.AX : 277.050 (-1.02%)
CSLLY : 93.2353 (+1.54%)
ARCT : 28.06 (+3.12%)
Finalization of Vifor Pharma acquisition

Regulatory News:

CSL.AX : 277.050 (-1.02%)
OTC.VN : 0.305 (+1.67%)
CSLLY : 93.2353 (+1.54%)
uniQure announces closing of commercialization and license agreement with CSL Behring

Upfront payment of $450 million due to uniQure by May 13, 2021

CSLLY : 93.2353 (+1.54%)
ASX : 10.27 (-1.63%)
QURE : 4.86 (-0.61%)
The Latest: Mexico to lower virus alert level in many states

MEXICO CITY __ Mexico is reducing its COVID-19 alert level in about half of the country’s states amid a drop in infections and hospitalizations in many places, including the capital.

PFE : 27.43 (-1.51%)
CSL : 409.36 (+0.21%)
CSLLY : 93.2353 (+1.54%)
The Latest: Australia's 2nd largest city to begin lockdown

MELBOURNE, Australia — Australia’s second-largest city will begin its third lockdown due to a rapidly spreading COVID-19 cluster centered on hotel quarantine.

JNJ : 149.52 (+0.38%)
CSL : 409.36 (+0.21%)
CSLLY : 93.2353 (+1.54%)
uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy

~ CSL Behring Obtains Exclusive Global Rights to Develop and Commercialize uniQure’s Differentiated Gene Therapy Candidate for Hemophilia B ~

ASX : 10.27 (-1.63%)
CSLLY : 93.2353 (+1.54%)
QURE : 4.86 (-0.61%)

Barchart Exclusives

Is This Outperforming Apple Supplier a Buy for Its 3% Yield?
Corning is a key Apple supplier that trades at a cheap valuation while offering investors a tasty dividend yield. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar